A combined ligand-based and target-based drug design approach for G-protein coupled receptors: application to salvinorin A, a selective kappa opioid receptor agonist
暂无分享,去创建一个
David M. Ferguson | Christopher R. McCurdy | Nidhi Singh | Gwénaël Chevé | D. Ferguson | Nidhi Singh | C. McCurdy | G. Chevé
[1] R J Knapp,et al. Identification of a human delta opioid receptor: cloning and expression. , 1994, Life sciences.
[2] N. Beeley,et al. GPCRs: an update on structural approaches to drug discovery , 2003 .
[3] R. E. Rhoads,et al. Progress in Molecular and Subcellular Biology , 1983, Progress in Molecular and Subcellular Biology.
[4] K. Palczewski,et al. Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.
[5] J. Thompson,et al. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.
[6] M. Caron,et al. Role of extracellular disulfide-bonded cysteines in the ligand binding function of the beta 2-adrenergic receptor. , 1990, Biochemistry.
[7] T. Klabunde,et al. Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. , 2005, Journal of medicinal chemistry.
[8] J. Thornton,et al. PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .
[9] H. C. Andersen. Molecular dynamics simulations at constant pressure and/or temperature , 1980 .
[10] A Ulloa-Aguirre,et al. Structure-activity relationships of G protein-coupled receptors. , 1999, Archives of medical research.
[11] Takeshi Hiramoto,et al. Identification of endogenous surrogate ligands for human P2Y receptors through an in silico search. , 2004, Journal of pharmacological sciences.
[12] Jeremy R. H. Tame,et al. Scoring functions: A view from the bench , 1999, J. Comput. Aided Mol. Des..
[13] R. Edwards,et al. Cloning of a delta opioid receptor by functional expression. , 1992, Science.
[14] Ulrike Holzgrabe,et al. Comparison of Pharmacological Activities of Three Distinct κ Ligands (Salvinorin A, TRK-820 and 3FLB) on κ Opioid Receptors in Vitro and Their Antipruritic and Antinociceptive Activities in Vivo , 2005, Journal of Pharmacology and Experimental Therapeutics.
[15] Bernard Maigret,et al. Rhodopsin crystal: new template yielding realistic models of G-protein-coupled receptors? , 2003, Trends in pharmacological sciences.
[16] A. Sali,et al. Comparative protein structure modeling of genes and genomes. , 2000, Annual review of biophysics and biomolecular structure.
[17] C Menzel,et al. Protein, lipid and water organization in bacteriorhodopsin crystals: a molecular view of the purple membrane at 1.9 A resolution. , 1999, Structure.
[18] L J Valdés,et al. Salvia divinorum and the unique diterpene hallucinogen, Salvinorin (divinorin) A. , 1994, Journal of psychoactive drugs.
[19] M. Karplus,et al. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .
[20] Christopher R. McCurdy,et al. Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist , 2006, Pharmacology Biochemistry and Behavior.
[21] Andreas Evers,et al. Virtual screening of biogenic amine-binding G-protein coupled receptors: comparative evaluation of protein- and ligand-based virtual screening protocols. , 2005, Journal of medicinal chemistry.
[22] T. Klabunde,et al. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. , 2002, Journal of medicinal chemistry.
[23] A. Scheer,et al. Constitutively active mutants of the alpha 1B‐adrenergic receptor: role of highly conserved polar amino acids in receptor activation. , 1996, The EMBO journal.
[24] G Vassart,et al. ORL1, a novel member of the opioid receptor family , 1994, FEBS letters.
[25] R Abagyan,et al. High-throughput docking for lead generation. , 2001, Current opinion in chemical biology.
[26] José-Luis Díaz,et al. Ethnopharmacology of ska María Pastora (Salvia divinorum, Epling and Játiva-M.). , 1983, Journal of ethnopharmacology.
[27] H Gobind Khorana,et al. Structural origins of constitutive activation in rhodopsin: Role of the K296/E113 salt bridge. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[28] Andrew R. Leach,et al. A comparison of the pharmacophore identification programs: Catalyst, DISCO and GASP , 2002, J. Comput. Aided Mol. Des..
[29] D. Rees,et al. Chemical structures and biological activities of non-peptide selective kappa opioid ligands. , 1992, Progress in medicinal chemistry.
[30] G. Uhl,et al. Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. , 1994, FEBS letters.
[31] S. Henikoff,et al. Amino acid substitution matrices from protein blocks. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[32] Robert P. Millar,et al. Functional Microdomains in G-protein-coupled Receptors , 1998, The Journal of Biological Chemistry.
[33] H Weinstein,et al. Comparative modeling and molecular dynamics studies of the delta, kappa and mu opioid receptors. , 1997, Protein engineering.
[34] Keun Woo Lee,et al. Molecular modeling study of the editing active site of Escherichia coli leucyl‐tRNA synthetase: Two amino acid binding sites in the editing domain , 2004, Proteins.
[35] P Ghanouni,et al. Agonist-induced conformational changes in the G-protein-coupling domain of the β2 adrenergic receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[36] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[37] K Konvicka,et al. A reciprocal mutation supports helix 2 and helix 7 proximity in the gonadotropin-releasing hormone receptor. , 1994, Molecular pharmacology.
[38] William M. Butler,et al. Divinorin A, a psychotropic terpenoid, and divinorin B from the hallucinogenic Mexican mint, Salvia divinorum , 1984 .
[39] G. Klebe,et al. Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. , 2004, Journal of medicinal chemistry.
[40] U. Gether. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. , 2000, Endocrine reviews.
[41] Y. Chen,et al. Molecular cloning of a rat kappa opioid receptor reveals sequence similarities to the mu and delta opioid receptors. , 1993, The Biochemical journal.
[42] Alan Wise,et al. Target validation of G-protein coupled receptors. , 2002, Drug discovery today.
[43] J. Bonfield,et al. Finishing the euchromatic sequence of the human genome , 2004, Nature.
[44] S. Mitaku,et al. Identification of G protein‐coupled receptor genes from the human genome sequence , 2002, FEBS letters.
[45] D J Siebert,et al. Salvia divinorum and salvinorin A: new pharmacologic findings. , 1994, Journal of ethnopharmacology.
[46] G. Klebe,et al. Ligand-supported homology modelling of protein binding-sites using knowledge-based potentials. , 2003, Journal of molecular biology.
[47] Paul D Lyne,et al. Structure-based virtual screening: an overview. , 2002, Drug discovery today.
[48] Andrew Smellie,et al. Poling: Promoting conformational variation , 1995, J. Comput. Chem..
[49] D. Rognan,et al. Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. , 2000, Journal of medicinal chemistry.
[50] Stefano Costanzi,et al. 2- and 8-alkynyladenosines: conformational studies and docking to human adenosine A3 receptor can explain their different biological behavior. , 2003, Journal of molecular graphics & modelling.
[51] Andrew Coop,et al. Kappa opioid antagonists: Past successes and future prospects , 2005, The AAPS Journal.
[52] A Ganesan,et al. Recent developments in combinatorial organic synthesis. , 2002, Drug discovery today.
[53] M. Menziani,et al. Synthesis, biological evaluation, and quantitative receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for kappa-opioid receptors. , 1996, Journal of medicinal chemistry.
[54] J. Ballesteros,et al. [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .
[55] Xueliang Fang,et al. Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach. , 2003, Journal of medicinal chemistry.
[56] Brigitte L. Kieffer,et al. Recent advances in molecular recognition and signal transduction of active peptides: Receptors for opioid peptides , 1995, Cellular and Molecular Neurobiology.
[57] E. Pebay-Peyroula,et al. X-ray structure of bacteriorhodopsin at 2.5 angstroms from microcrystals grown in lipidic cubic phases. , 1997, Science.
[58] Gisbert Schneider,et al. Virtual screening and fast automated docking methods. , 2002, Drug discovery today.
[59] Andrew C. Good,et al. High-throughput and Virtual Screening: Core Lead Discovery Technologies Move Towards Integration , 2000 .
[60] T. Schwartz,et al. Construction of a High Affinity Zinc Switch in the -Opioid Receptor (*) , 1996, The Journal of Biological Chemistry.
[61] P. Gund. Three-Dimensional Pharmacophoric Pattern Searching , 1977 .
[62] D C Teller,et al. Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs). , 2001, Biochemistry.
[63] K. Befort,et al. The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[64] J. Meunier,et al. Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor. , 1997, European journal of pharmacology.
[65] Bryan L. Roth,et al. Salvinorin A: a novel and highly selective kappa-opioid receptor agonist. , 2004, Life sciences.
[66] Aalt Bast,et al. Comprehensive medicinal chemistry , 1991 .
[67] G. Bell,et al. Cloning and functional comparison of kappa and delta opioid receptors from mouse brain. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[68] Marcus Elstner,et al. The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure. , 2004, Journal of molecular biology.
[69] Bryan L. Roth,et al. Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[70] Maria Jesus Martin,et al. The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003 , 2003, Nucleic Acids Res..
[71] D R Flower,et al. Modelling G-protein-coupled receptors for drug design. , 1999, Biochimica et biophysica acta.
[72] P Willett,et al. Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.
[73] Gerd Folkers,et al. Integrated Homology Modelling and X-Ray Study of Herpes Simplex Virus I Thymidine Kinase , 1998 .
[74] Bryan L Roth,et al. Identification of the Molecular Mechanisms by Which the Diterpenoid Salvinorin A Binds to κ-Opioid Receptors† , 2005 .
[75] D R Flower,et al. Lead generation using pharmacophore mapping and three-dimensional database searching: application to muscarinic M(3) receptor antagonists. , 1999, Journal of medicinal chemistry.
[76] Cécile Béguin,et al. Synthesis and in vitro pharmacological evaluation of salvinorin A analogues modified at C(2). , 2005, Bioorganic & medicinal chemistry letters.
[77] J. Briggs,et al. Structure-based drug design: computational advances. , 1997, Annual review of pharmacology and toxicology.
[78] Stanley J. Watson,et al. Cloning and pharmacological characterization of a rat μ opioid receptor , 1993, Neuron.
[79] J. Ballesteros,et al. G protein-coupled receptor drug discovery: implications from the crystal structure of rhodopsin. , 2001, Current opinion in drug discovery & development.
[80] Harald Schwalbe Prof.,et al. Editorial: Dissecting G-Protein-Coupled Receptors: Structure, Function, and Ligand Interaction , 2002 .
[81] D. L. Larson,et al. Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists. , 1998, Journal of medicinal chemistry.
[82] Ruth Nussinov,et al. Principles of docking: An overview of search algorithms and a guide to scoring functions , 2002, Proteins.
[83] Shay Bar-Haim,et al. G protein-coupled receptors: in silico drug discovery in 3D. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[84] Tudor I. Oprea,et al. Integrating virtual screening in lead discovery. , 2004, Current opinion in chemical biology.
[85] Natasja Brooijmans,et al. Molecular recognition and docking algorithms. , 2003, Annual review of biophysics and biomolecular structure.
[86] T. Schwartz,et al. Radioligand-dependent discrepancy in agonist affinities enhanced by mutations in the kappa-opioid receptor. , 1996, Molecular pharmacology.
[87] Philip S. Portoghese,et al. Application of the message-address concept to the docking of naltrexone and selective naltrexone-derived opioid antagonists into opioid receptor models , 1996, Neurochemical Research.
[88] Krzysztof Palczewski,et al. Role of the conserved NPxxY(x)5,6F motif in the rhodopsin ground state and during activation , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[89] Harald Schwalbe,et al. Editorial: Dissecting G‐Protein‐Coupled Receptors: Structure, Function, and Ligand Interaction , 2002, Chembiochem : a European journal of chemical biology.
[90] J. Drews. Drug discovery: a historical perspective. , 2000, Science.
[91] M. Saraste,et al. FEBS Lett , 2000 .
[92] Markus Eilers,et al. Changes in interhelical hydrogen bonding upon rhodopsin activation. , 2005, Journal of molecular biology.
[93] H. Khorana,et al. Requirement of Rigid-Body Motion of Transmembrane Helices for Light Activation of Rhodopsin , 1996, Science.
[94] Christopher R McCurdy,et al. A unique binding epitope for salvinorin A, a non‐nitrogenous kappa opioid receptor agonist , 2006, The FEBS journal.
[95] Rainer E. Martin,et al. Ligand identification for G-protein-coupled receptors: a lead generation perspective. , 2004, Current opinion in chemical biology.
[96] Penelope W. Codding. Structure-based drug design : experimental and computational approaches , 1998 .
[97] Thomas E Prisinzano,et al. Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands. , 2005, Journal of medicinal chemistry.
[98] E. Hulme,et al. The conformational switch in 7-transmembrane receptors: the muscarinic receptor paradigm. , 1999, European journal of pharmacology.
[99] Vsevolod V Gurevich,et al. Differential interaction of spin-labeled arrestin with inactive and active phosphorhodopsin. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[100] M. Nishi,et al. Primary structures and expression from cDNAs of rat opioid receptor δ‐and μ‐subtypes , 1993 .
[101] Michael Mosher,et al. Acute Physiologic and Chronic Histologic Changes in Rats and Mice Exposed to the Unique Hallucinogen Salvinorin A , 2003, Journal of psychoactive drugs.
[102] A Goldstein,et al. Cloning and pharmacological characterization of a rat kappa opioid receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[103] Didier Rognan,et al. Protein‐based virtual screening of chemical databases. II. Are homology models of g‐protein coupled receptors suitable targets? , 2002, Proteins.
[104] Graham Bell,et al. Phenotypic consequences of 1,000 generations of selection at elevated CO2 in a green alga , 2004, Nature.
[105] F. Young. Biochemistry , 1955, The Indian Medical Gazette.
[106] G Vriend,et al. Heavier‐than‐air flying machines are impossible , 2004, FEBS letters.
[107] L. Bare,et al. Isolation of a Human κ Opioid Receptor cDNA from Placenta , 1994 .
[108] H Gobind Khorana,et al. Rhodopsin structure, dynamics, and activation: a perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity, and disulfide cross-linking. , 2003, Advances in protein chemistry.
[109] Lei Yu,et al. Molecular cloning and functional expression of a mu opioid receptor from rat brain , 1994, Regulatory Peptides.
[110] Irina D. Pogozheva,et al. Homology modeling of opioid receptor-ligand complexes using experimental constraints , 2005, The AAPS Journal.
[111] Jonathan W. Essex,et al. A review of protein-small molecule docking methods , 2002, J. Comput. Aided Mol. Des..
[112] H Weinstein,et al. Related Contribution of Specific Helix 2 and 7 Residues to Conformational Activation of the Serotonin 5-HT2A Receptor (*) , 1995, The Journal of Biological Chemistry.
[113] Jürgen Bajorath,et al. Selected Concepts and Investigations in Compound Classification, Molecular Descriptor Analysis, and Virtual Screening , 2001, J. Chem. Inf. Comput. Sci..
[114] J. S. Dixon,et al. Evaluation of the CASP2 docking section , 1997, Proteins.
[115] Bruce Cohen,et al. Synthesis and in vitro pharmacological studies of new C(2) modified salvinorin A analogues. , 2005, Bioorganic & medicinal chemistry letters.
[116] Bo Li,et al. Identification of an Agonist-induced Conformational Change Occurring Adjacent to the Ligand-binding Pocket of the M3 Muscarinic Acetylcholine Receptor* , 2005, Journal of Biological Chemistry.
[117] A. Lomize,et al. Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints. , 1998, Biophysical journal.
[118] T. Blundell,et al. Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.
[119] G. Klebe,et al. Statistical potentials and scoring functions applied to protein-ligand binding. , 2001, Current opinion in structural biology.
[120] Bryan L Roth,et al. Salvinorin A, an Active Component of the Hallucinogenic Sage Salvia divinorum Is a Highly Efficacious κ-Opioid Receptor Agonist: Structural and Functional Considerations , 2004, Journal of Pharmacology and Experimental Therapeutics.
[121] Bryan L Roth,et al. Studies toward the pharmacophore of salvinorin A, a potent kappa opioid receptor agonist. , 2005, Journal of medicinal chemistry.